Progress on the development of Class A GPCR-biased ligands

Area of Science:

• Pharmacology
• Molecular Biology
• Drug Discovery

Background:

• Class A G protein-coupled receptors (GPCRs) are crucial for cell signaling and are important drug targets.
• Despite existing drugs, over 60% of GPCRs remain unexploited due to limitations of unbiased modulators.
• Adverse effects of current GPCR modulators necessitate novel therapeutic strategies.

Purpose of the Study:

• To review the current drug discovery landscape of biased GPCR modulators.
• To highlight recent advances in functionally selective ligands for Class A GPCRs.
• To analyze the therapeutic relevance, molecular basis, and clinical applications of these modulators.

Main Methods:

• Literature review of recent publications on GPCR-biased signaling.
• Compilation and analysis of functionally selective modulators for individual Class A GPCR families.
• Dissection of therapeutic relevance, molecular determinants, and clinical potential.

Main Results:

• Biased signaling offers new avenues for developing safer therapeutics by targeting specific receptor conformations.
• Functionally selective ligands preferentially activate distinct signaling pathways, improving therapeutic specificity.
• Understanding of biased signaling varies across different Class A GPCR families, with ongoing research into their specific effects.

Conclusions:

• Biased GPCR modulators represent a promising frontier in drug discovery, offering improved safety and efficacy.
• Targeting specific receptor-effector interactions can overcome limitations of traditional GPCR drugs.
• Further research into individual GPCR families is essential for realizing the full clinical potential of biased signaling.